New Drug Lead for African Sleeping Sickness
Author Information
Author(s): Deuan C. Jones, Irene Hallyburton, Laste Stojanovski, Kevin D. Read, Julie A. Frearson, Alan H. Fairlamb
Primary Institution: University of Dundee
Hypothesis
Can a κ-opioid agonist be a selective lead for drug development against human African trypanosomiasis?
Conclusion
The κ-opioid agonist (+)-U50,488 shows promise as a selective lead for drug development against sleeping sickness, although it was not curative in mouse models.
Supporting Evidence
- The study identified 33 compounds with EC50 values less than 1 μM against T. brucei.
- The most selective novel inhibitor was (+)-trans-(1R,2R)-U50,488 with an EC50 of 60 nM.
- The compound showed good brain penetration and was well tolerated by the oral route.
Takeaway
Scientists found a new drug that might help treat a disease caused by a parasite in Africa, but it didn't completely cure the disease in mice.
Methodology
Phenotypic screening of the LOPAC library was conducted using a resazurin-based cell viability assay against T. brucei and human fibroblasts.
Limitations
The compound was not curative in the mouse model of infection and showed only cytostatic effects at therapeutic concentrations.
Participant Demographics
Mice were used for in vivo studies, specifically NMRI outbred mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website